Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3927]

The clinical value of maintenance in multiple myeloma

Prof Wee Joo Chng - National University of Singapore, Singapore

The clinical value of maintenance in multiple myeloma ( Prof Wee Joo Chng - National University of Singapore, Singapore )

Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non...

Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA

$Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients ( Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA )$

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

Latest updates in exon 20 insertions focusing on targeted therapies, novel...

Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients ( Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho )

JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care...

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (BSC) versus BSC alone for advanced UC ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin...

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

COVID-19 and cancer: Highlights from ASCO 2021

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

COVID-19 and cancer: Highlights from ASCO 2021 ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non...

Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )

Efficacy and safety of tisagenlecleucel in adult patients with relapsed...

Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA

$Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma ( Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA )$

Clinical research and trials in Romania

Dr Michael Schenker - University of Medicine and Pharmacy Craiova, Center of...

Clinical research and trials in Romania ( Dr Michael Schenker - University of Medicine and Pharmacy Craiova, Center of Oncology Sf Nectarie )

First results of a head-to-head trial of acalabrutinib versus ibrutinib in...

Dr John Byrd - The Ohio State University, Columbus, USA

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )

Breast cancer roundup from ASCO 2021

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Breast cancer roundup from ASCO 2021 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

More from ecancer